Powered by BiozThis cell line is a modified version of CREM004i-SS2-1, engineered to correct the mutation in HBB(E6V). This isogenic control is unaffected. An unmodified, affected isogenic cell line, CREM004i-SS2-1, is available from WiCell.
**Upon testing, the current lot of material did not meet WiCell’s standards for quality, and it is therefore unavailable. WiCell is working with the Provider to obtain replacement materials for distribution. To be notified of the status of this cell line please submit your information here.
- Cell Line Alias SCD iPSC SS.2-1-GAG, SS2-1GAG
- Unit of Measure (UOM) vial
- Cell Type Modified Human iPS
- Sex Female
- Age at Collection 32 Years
- Ethnicity Information Physician reported
- Reprogramming Method Viral transfection (Lentivirus: Oct4, Klf4, Sox2, cMyc)
- Tissue Origin Blood
- Genetic Alteration Mutation Information A>T mutation in beta globin gene reverted to A by CRISPRs
- Genetic Modification Keyword Isogenic; Sickle cell
- Disease None reported
- Ethnicity African American
- Genetic Alteration Mutation HBB(E6V) Corrected
- Pubmed Abstract Park Seonmi, et al "A Comprehensive, Ethnically Diverse Library of Sickle Cell Disease-Specific Induced Pluripotent Stem Cells." Stem Cell Reports 8(4) (2017): 1076-1085.
- dbGap Data phs001212
- Provider Boston University and Boston Medical Center's Center for Regenerative Medicine (CReM) - Dr. Steinberg, Dr. Mostoslavsky, Dr. Murphy
- Collections NHLBI Next Gen - Sickle Cell Anemia (Dr. Steinberg, Dr. Mostoslavsky, Dr. Murphy, Boston University and Boston Medical Center's Center for Regenerative Medicine)
| Lot Number | Culture Platform | Lot Description | Banked By | Passage Number | Protocol | Product Info URL |
| DB66769 | mTeSR1/Matrigel | Provider | 39 | WiCell Feeder Independent Pluripotent Stem Cell Protocol |